The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients

We presented the rationale for the use of thymosin α1 as prophylaxis of severe COVID-19 in cancer patients undergoing active treatment, constituting the background for the PROTHYMOS study, a prospective, multicenter, open-label, Phase II randomized study, currently in its start-up phase (Eudract no....

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Future Oncol
Autors principals: Bersanelli, Melissa, Giannarelli, Diana, Leonetti, Alessandro, Buti, Sebastiano, Tiseo, Marcello, Nouvenne, Antonio, Ticinesi, Andrea, Meschi, Tiziana, Procopio, Giuseppe, Danielli, Riccardo
Format: Artigo
Idioma:Inglês
Publicat: Future Medicine Ltd 2021
Matèries:
Special Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7874885/
https://ncbi.nlm.nih.gov/pubmed/33538178
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/fon-2020-0754
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars